PARADIGM BIOPHARMACEUT.

Paradigm Biopharmaceuticals shares surged nearly 25% after announcing a $41 million loan to fund its osteoarthritis clinical investigations. The company also issued convertible securities at 75cps, indicating confidence in future share price growth, and emphasized that the funding is non-dilutive for existing shareholders. The funds are expected to support the company through mid-2026, enabling progress in its phase 3 clinical program. » Plus sur themarketonline.com.au

Paradigm Biopharmaceutical has agreed to acquire Proteobioactives Pty Ltd for $16.5 million, gaining access to Pentacoxib, an early-stage oral treatment for minor to mild osteoarthritis. Managing director Paul Rennie stated the acquisition complements Paradigm's ongoing phase three clinical trials for its injectable PPS while enabling future development of the oral drug. The company will maintain its current focus but sees the acquisition as a strategic long-term addition. » Plus sur themarketonline.com.au

The ASX200 closed flat, mirroring Wall Street, with IT, Real Estate, and Industrials sectors under pressure, while Health Care and Financials outperformed. Paradigm Biopharmaceuticals jumped after acquiring Proteobioactives and securing global patent rights to a new oral therapy. Other notable moves included Civmec rising on an acquisition deal, European Lithium gaining after an off-market sale, and declines in Gladiator Resources, Bannerman Energy, and Strike Energy following company updates. » Plus sur themarketonline.com.au